Fierce Pharma Asia—Historic solid tumor CAR-T nod; Inside Pfizer, Innovent’s $10B pact; More China deals

In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a behind-the-scenes look at Pfizer and Innovent Biologics' $10.5 billion cancer deal r | In the past two weeks, CARsgen won the world's first approval for a solid tumor CAR-T, a behind-the-scenes look at Pfizer and Innovent Biologics' $10.5 billion cancer deal revealed a less-than-five-month sprint, Daiichi Sankyo's new R&D chief discussed how he plans to keep the antibody-drug conjugate leader ahead in the game, and a flurry of China licensing deals with various structures have emerged.